دورية أكاديمية

A randomized, placebo-controlled, double-blind trial to evaluate efficacy and safety of Shen-Yuan-Dan capsules, a traditional Chinese medicine, for treatment of peri-procedure myocardial injury following percutaneous coronary intervention

التفاصيل البيبلوغرافية
العنوان: A randomized, placebo-controlled, double-blind trial to evaluate efficacy and safety of Shen-Yuan-Dan capsules, a traditional Chinese medicine, for treatment of peri-procedure myocardial injury following percutaneous coronary intervention
المؤلفون: Xiang Li, Ying Zhang, Hong-Xu Liu, Ju-Ju Shang, Qi Zhou, Ai-Yong Li, Xiao-Lei Lai, Wen-Long Xing, Si-Han Jia
المصدر: Complementary Therapies in Medicine, Vol 69, Iss , Pp 102841- (2022)
بيانات النشر: Elsevier, 2022.
سنة النشر: 2022
المجموعة: LCC:Other systems of medicine
مصطلحات موضوعية: Peri-procedural myocardial injury (PMI), Percutaneous coronary intervention (PCI), Traditional Chinese medicine (TCM), Randomized controlled trials, Other systems of medicine, RZ201-999
الوصف: Background: Peri-procedural myocardial injury (PMI) is a common complication of percutaneous coronary intervention (PCI), which cannot be entirely avoided using available treatments. The findings of earlier research have shown that Shen-Yuan-Dan (SYD) capsules, a traditional Chinese medicine, can potentially alleviating PMI. This study aimed to confirm further this hypothesis in a rigorous, well-designed randomized controlled study. Methods: Our clinical trial was randomized, double-blinded, and placebo-controlled. A total of 181 patients with unstable angina (UA) undergoing elective PCI were randomized to pretreatment with SYD or a placebo under the basis of conventional treatment; 87 patients were pretreated with SYD (4 capsules, 3 times a day, with a further 4 capsules 2 h before PCI) 3 days before the procedure, and 94 patients were given a placebo. No patients received reloading statins before PCI, and SYD or placebo was maintained for 1 month after PCI. The primary endpoint was the incidence of PMI. The secondary endpoint was calculating the incidence rate of all 30-day major adverse cardiovascular events (all-cause mortality, non-fatal myocardial infarction, unplanned revascularization). The safety outcomes, including abnormalities in electrocardiogram and serum biochemical examinations caused by drug use, were also tested. Results: The levels of creatine kinase-myocardial band (CK-MB) in both the SYD and placebo groups were increased at 4 h and 24 h after PCI compared with before the procedure (P
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 0965-2299
Relation: http://www.sciencedirect.com/science/article/pii/S0965229922000437; https://doaj.org/toc/0965-2299
DOI: 10.1016/j.ctim.2022.102841
URL الوصول: https://doaj.org/article/f40bd41c137a44b89f938103baf2310f
رقم الأكسشن: edsdoj.f40bd41c137a44b89f938103baf2310f
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:09652299
DOI:10.1016/j.ctim.2022.102841